PathAI

PathAI is building AI-powered pathology tools that improve the accuracy and efficiency of disease diagnosis, with a focus on oncology and liver disease. The company's AI models analyze digital pathology images to identify cancer subtypes, quantify biomarkers, and provide diagnostic insights that help pathologists make more accurate and consistent assessments.

PathAI's platform serves both clinical diagnostics and pharmaceutical drug development. For clinical labs, the company's AISight diagnostic suite provides AI-assisted analysis that improves diagnostic consistency. For pharma companies, PathAI's research platform enables AI-powered biomarker discovery and patient stratification in clinical trials.

The company has raised over $250 million in venture funding and partnered with major pharmaceutical companies including Bristol-Myers Squibb, Roche, and AstraZeneca. PathAI's approach combines computer vision AI with deep pathology expertise to address one of medicine's most critical bottlenecks — the shortage of expert pathologists.